Silence Therapeutics plc (SLN) Institutional Ownership

Ownership Summary

Silence Therapeutics plc (NASDAQ:SLN) is held by 54 institutional investors per 13F filings through September 2025.

• Collectively, these holders controlled 15.0% of Silence Therapeutics's outstanding shares in September 2025, up from 13.2% in June 2025.
• Their total shares held in SLN increased 15.52% from the prior quarter, while the number of investors in Silence Therapeutics stayed flat year over year.
• Of these 54 funds, 22 grew their exposure to Silence Therapeutics, 15 cut back, and 17 maintained positions.
• Combined, these investors held 21.32Mn shares in SLN for September 2025, up by 2.86Mn shares quarter on quarter, and up 715.48K shares year over year.
• TCG Crossover Management, LLC leads ownership in SLN with 3.03Mn shares as of September 30, 2025, equal to 2.14% of outstanding shares.
• Leading buyers of Silence Therapeutics shares for the quarter ending September 2025 were CITADEL ADVISORS LLC (990.75K), Nantahala Capital Management, LLC (604.3K), MILLENNIUM MANAGEMENT LLC (414.6K), Jones Hill Capital LP (301.6K), Tetragon Partners GP Ltd (264.79K).
• The largest sales of SLN for the quarter ending September 2025 came from Morgan Stanley (259.14K), HSBC HOLDINGS PLC (222.83K), Seven Fleet Capital Management LP (138.44K), Ishara Investments LP (99.5K), M28 Capital Management LP (83.9K).
• According to Business Quant data, leading holders of SLN for September 2025 are TCG Crossover Management, LLC (3.03Mn), Siren, L.L.C. (2.91Mn), Redmile Group, LLC (2.16Mn), Nantahala Capital Management, LLC (2.15Mn), CITADEL ADVISORS LLC (1.23Mn), MILLENNIUM MANAGEMENT LLC (1.07Mn), GREAT POINT PARTNERS LLC (1.02Mn), Nextech Invest, Ltd. (952.4K), Ikarian Capital, LLC (865.78K), Tetragon Partners GP Ltd (630.16K).